Clicky

Betta Pharmaceuticals Co Ltd(300558)

Description: Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.


Keywords: Cancer Organic Compounds Chemical Compounds Treatment Of Cancer Non Small Cell Lung Cancer Lung Cancer Enzymes Protein Kinase Inhibitor Non Small Cell Lung Carcinoma Tyrosine Kinase Treatment Of Non Small Cell Lung Cancer Tyrosine Kinase Receptors Tyrosine Kinase Inhibitors Anaplastic Lymphoma Kinase Icotinib

Home Page: www.bettapharma.com

No. 355, Xingzhong Road
Hangzhou,
China
Phone: 86 571 8613 0357


Officers

Name Title
Mr. Lieming Ding Founder, Chairman of Directors, CEO & GM
Mr. Fan Jianxun VP & Chief Financial Officer
Mr. Jiang Wan Sr. VP, Chief Operations Officer & Non Independent Director
Mr. Jiabing Wang Sr. VP, Chief Scientific Officer & Non Independent Director
Mr. Lingxi Wu Independent Director and Board Sec.
Dr. Yinxiang Wang Pres
Dr. Xinshan Kang Chief Scientist in Drug Discovery
Mr. Wanyu Cai Sr. VP
Mr. Hao Wu Sr. Director, Head of Hangzhou R&D Center and Supervisor
Mr. Wenxin Xu Sr. Director & Head of Immunology

Exchange: SHE

Country: CN

Currency: Renminbi (¥)

Forward PE: 0
Trailing PE: 183.8182
Price-to-Book MRQ: 4.3194
Price-to-Sales TTM: 9.6776
IPO Date:
Fiscal Year End: December
Full Time Employees: 1677
Back to stocks